Blue Owl Capital Holdings
Blue Owl Capital Holdings reported 73 stocks worth $546M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are SPCX (25.5%), AKTS (11.9%) and LTGO (11.0%). Compared with Q2 2026, the fund opened new positions in LTGO, ETRA and OBX, added to AKTS, LRMR and AQST, trimmed SPCX, CGEM and SGMT and sold out of COF, EYPT and RYTM.
Latest filing: what Blue Owl Capital Holdings did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() SPCX Space Exploration Techn Corp Class A Com Stk | $139M | 25.5% | 923K | −476K (−34%) | 2 of 8 | |
| 2 | ![]() AKTS Aktis Oncology Inc | $65.1M | 11.9% | 3.3M | +274K (+9%) | 3 of 8 | |
| 3 | ![]() LTGO Latigo Biotherapeutics | $60.1M | 11.0% | 3.6M | New position | 1 of 8 | |
| 4 | ![]() LRMR Larimar Therapeutics Inc | $31.7M | 5.8% | 9.9M | +761K (+8%) | 8 of 8 | |
| 5 | ![]() ETRA Electra Therapeutics Inc | $29.4M | 5.4% | 2.6M | New position | 1 of 8 | |
| 6 | ![]() NCDL Nuveen Churchill Direct Lend Com SH | $24.1M | 4.4% | 2.1M | No change | 8 of 8 | |
| 7 | ![]() CGEM Cullinan Therapeutics Inc | $21.5M | 3.9% | 1.4M | −140K (−9%) | 8 of 8 | |
| 8 | ![]() OBDC Blue Owl Capital Corporation | $21.5M | 3.9% | 2M | No change | 8 of 8 | |
| 9 | ![]() OBX Obsidian Therapeutics Inc | $20.4M | 3.7% | 1.5M | New position | 1 of 8 | |
| 10 | ![]() SGMT Sagimet Biosciences Inc | $11.1M | 2.0% | 1.1M | −135K (−11%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() COF Capital One Finl Corp | $24M | 120K |
![]() EYPT Eyepoint Pharmaceuticals Inc | $10.9M | 763K |
![]() RYTM Rhythm Pharmaceuticals Inc | $6.8M | 61K |
![]() CMPS Compass Pathways PLC | $6.4M | 450K |
![]() RARE Ultragenyx Pharmaceutical in | $6.1M | 183K |
🔒 Free account: see all 14.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() CMPS Compass Pathways PLC | Call | $888K | 800K | −870,500 |
![]() SGMT Sagimet Biosciences Inc | Call | $201K | 365K | +365,400 |
![]() VKTX Viking Therapeutics Inc | Call | $181K | 300K | +300,000 |
![]() ELDN Eledon Pharmaceuticals Inc | Call | $100K | 200K | 0 |
![]() CMPX Compass Therapeutics Inc | Call | $49K | 620K | +315,900 |
🔒 Free account: see all 6.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 13, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Blue Owl Capital Holdings 13F FAQ
What does Blue Owl Capital Holdings own?
Blue Owl Capital Holdings reported 73 stocks worth $546M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are SPCX (25.5%), AKTS (11.9%) and LTGO (11.0%). The table above lists every position in the filing (the top 10 without an account).
What did Blue Owl Capital Holdings buy and sell in Q3 2026?
Compared with Q2 2026: 16 new positions, 7 added to, 13 trimmed and 14 sold out. New positions include LTGO, ETRA and OBX. It sold all of COF, EYPT and RYTM.
When will Blue Owl Capital Holdings file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Blue Owl Capital Holdings's portfolio worth?
The Q3 2026 filing reports $546M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.

























